The chief financial officer of Thousand Oaks drug maker Amgen Inc. has stepped down amid growing worries that the company was not honest with shareholders about product safety concerns. Robert Nanula will resign within 90 days and will be replaced by Robert Bradway, who came to the company in August as vice president of operations strategy. The resignation comes as Amgen is under investigation by the Securities and Exchange Commission after it delayed releasing the findings of a study that showed its Aranesp drug was not effective in some patients. The Food and Drug Administration is also looking into how Amgen markets Aranesp and Epogen and lawmakers are investigating whether the company held back important safety information. Additionally, the company said it plans to delay reporting first-quarter results until April 23 so it will include results from a new Aranesp trail on small cell lung cancer patients receiving therapy.
